Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)
Fuyuhiko Motoi(Tohoku University), Masayuki Sho(Nara Medical University), Goro Honda(Tokyo Metropolitan Komagome Hospital), Hideki Ueno(National Defense Medical College), Junji Furuse(Kanagawa Prefectural Hospital Organization), Hiroki Yamaue(Wakayama Medical University), Sohei Satoi(Kansai Medical University), Michiaki Unno(Tohoku University), Yutaka Matsuyama(The University of Tokyo), Tomoo Kosuge(Tokyo National Hospital), Ippei Matsumoto(Kindai University), Keita Wada(Teikyo University)
Cited by 534
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective
|The Oncologist|2010|977